Holocene Advisors’s Fulcrum Therapeutics FULC Stock Holding History

Holocene Advisors’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-864,978	Closed	-$15.3M	–	919
2021 Q4	$15.3M	Buy	+864,978	New	+$17.1M	0.08%	213

Other funds holding FULC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Holocene Advisors's FULC Position: Q1 2022 in Review

Holocene Advisors sold out of Fulcrum Therapeutics (FULC) in Q1 2022, closing a stake of 864,978 shares — an estimated $15.3M sold.

Holocene Advisors first reported a position in FULC in Q4 2021 and held it in 1 quarter. The position peaked at $15.3M in Q4 2021. 108 funds tracked by Wall St. Rank hold FULC as of Q1 2022.

Holocene Advisors reported no remaining Fulcrum Therapeutics position as of Q1 2022 after selling out during the quarter.
Holocene Advisors sold 864,978 Fulcrum Therapeutics shares in Q1 2022, an estimated $15.3M.
Holocene Advisors first reported a position in Fulcrum Therapeutics in Q4 2021 and held it in 1 quarter.
Holocene Advisors's Fulcrum Therapeutics position peaked at $15.3M in Q4 2021.
108 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2022.

Based on Holocene Advisors's 13F filing for Q1 2022, filed 16 May 2022.